BeOne Medicines Ltd. 4

CEO John Oyler of BeOne Medicines Ltd. exercised options into ADSs and ordinary shares and sold 64,628 ADSs under a 10b5-1 plan for about $19.7 million on July 17, 2026.

On July 17, 2026, BeOne Medicines Ltd. CEO John Oyler exercised 64,628 American Depositary Shares (ADSs) at an effective price of $119.96 per ADS (via conversion of options denominated in ordinary shares) and concurrently sold the same 64,628 ADSs in a series of 10b5-1–planned open‑market transactions at prices ranging from approximately $305.20 to $315.06 per ADS, generating gross sale proceeds of roughly $19.7 million; he also exercised a separate share option for 840,164 ordinary shares at a $9.23 exercise price, which increased his direct ownership in ordinary shares to 441,870, while large additional ordinary share positions are held indirectly through various trusts and an LLC for which he generally disclaims beneficial ownership.

Filing Facts

CIK

1651308

Ticker

ONC

Form

4

Source Type

fda

Accession

0001042047-26-000015

Alert Tier

7